Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Finished Goods (2022 - 2026)

Envoy Medical's Finished Goods history spans 5 years, with the latest figure at $196000.0 for Q1 2026.

  • On a quarterly basis, Finished Goods rose 19.51% to $196000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $196000.0, a 19.51% increase, with the full-year FY2025 number at $196000.0, up 64.71% from a year prior.
  • Finished Goods hit $196000.0 in Q1 2026 for Envoy Medical, roughly flat from $196000.0 in the prior quarter.
  • Over the last five years, Finished Goods for COCH hit a ceiling of $196000.0 in Q4 2025 and a floor of $84000.0 in Q4 2023.
  • Historically, Finished Goods has averaged $135333.3 across 5 years, with a median of $125500.0 in 2022.
  • Biggest five-year swings in Finished Goods: tumbled 30.58% in 2023 and later skyrocketed 64.71% in 2025.
  • Tracing COCH's Finished Goods over 5 years: stood at $121000.0 in 2022, then tumbled by 30.58% to $84000.0 in 2023, then skyrocketed by 41.67% to $119000.0 in 2024, then skyrocketed by 64.71% to $196000.0 in 2025, then changed by 0.0% to $196000.0 in 2026.
  • Business Quant data shows Finished Goods for COCH at $196000.0 in Q1 2026, $196000.0 in Q4 2025, and $165000.0 in Q3 2025.